Luye Pharma Group Ltd.
LYPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $3,181 | $2,987 | $3,075 | $3,239 |
| % Growth | 6.5% | -2.9% | -5.1% | – |
| Cost of Goods Sold | $1,024 | $1,021 | $996 | $978 |
| Gross Profit | $2,158 | $1,966 | $2,079 | $2,261 |
| % Margin | 67.8% | 65.8% | 67.6% | 69.8% |
| R&D Expenses | $193 | $218 | $281 | $291 |
| G&A Expenses | $315 | $293 | $289 | $347 |
| SG&A Expenses | $1,334 | $1,258 | $1,140 | $1,288 |
| Sales & Mktg Exp. | $1,019 | $966 | $851 | $941 |
| Other Operating Expenses | $0 | -$144 | $0 | $0 |
| Operating Expenses | $1,528 | $1,332 | $1,421 | $1,579 |
| Operating Income | $630 | $633 | $658 | $682 |
| % Margin | 19.8% | 21.2% | 21.4% | 21.1% |
| Other Income/Exp. Net | -$172 | -$324 | -$128 | -$211 |
| Pre-Tax Income | $458 | $309 | $530 | $471 |
| Tax Expense | $100 | $102 | $92 | $77 |
| Net Income | $313 | $84 | $388 | $383 |
| % Margin | 9.8% | 2.8% | 12.6% | 11.8% |
| EPS | 0.083 | -0.083 | 0.1 | 0.102 |
| % Growth | 200.8% | -182.5% | -1.8% | – |
| EPS Diluted | 0.083 | -0.083 | 0.1 | 0.102 |
| Weighted Avg Shares Out | 3,762 | 3,762 | 3,762 | 3,762 |
| Weighted Avg Shares Out Dil | 3,762 | 3,762 | 3,762 | 3,762 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $84 | $0 | $210 |
| Interest Expense | $0 | $562 | $0 | $0 |
| Depreciation & Amortization | $393 | $456 | $335 | $348 |
| EBITDA | $1,004 | $1,252 | $939 | $1,029 |
| % Margin | 31.5% | 41.9% | 30.6% | 31.8% |